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We describe the case of a 58-year-old man who presented with progressive dyspnoea on exertion and
severe exertional hypoxia. There was a paucity of radiological ﬁndings, mild pulmonary hypertension,
and no demonstrable anatomical shunt. Post mortem examination of lung tissue suggested a diagnosis of
pulmonary capillary haemangiomatosis. The case is unusual in displaying few radiological ﬁndings. We
postulate that the severe hypoxia was due to shunting through the abnormal capillary proliferations.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Case report
A 58-year-old man presented with a 2-year history of progres-
sive exertional dyspnoea. He had smoked 30 cigarettes daily, but
had ceased smoking 10 years before presentation. There was
a history of systemic hypertension treated with an angiotensin
converting enzyme inhibitor. There was no other medical history of
note and in particular no history of chronic liver disease or hered-
itary haemorrhagic telangiectasia. Physical examination was
unremarkable with no signs of cardiac defeat, no cardiac murmurs
and no adventitial sounds on auscultation of the chest. Chest X-ray
showed no abnormality. Spirometry showed an FEV1 of 3.52 l (110%
predicted), and an FVC of 4.36 l (105% predicted), (FEV1/FVC 81%).
Carbon monoxide diffusing capacity was 49% predicted. High
resolution CT scans showed no signiﬁcant lung parenchymal
abnormality. A CT pulmonary angiogram showed no thromboem-
bolic disease. An isotope ventilation perfusion scan was unre-
markable. A cardiopulmonary exercise test showed slightly reduced
exercise tolerance with maximum oxygen consumption of
23.2 ml kg1 min1 (81% predicted). The exercise test also showed
marked desaturation measured by pulse oximetry (95% at rest to
77% at peak exercise), low end-tidal partial pressure of carbon
dioxide (maximum value of 32 mmHg) and high ventilatory
equivalent for CO2 (nadir value of 39), all suggesting ventilation
perfusion mismatch or shunt. Contrast echocardiography showed
no intra cardiac shunt and otherwise normal appearances. Cardiacx: þ44 2890 263546.
et (M.S. Riley).
-NC-ND license.catheterisation showed a mean right atrial pressure of 5 mmHg,
a mild increase in pulmonary artery pressure with mean of
26 mmHg, normal pulmonary capillary wedge pressure of
10 mmHg, cardiac output of 4.7 l min1, and cardiac index of
4.13 l min1 m2. Pulmonary vascular resistance was slightly
elevated at 3.4 Wood Units.
He continued to deteriorate symptomatically. Twelve months
later, spirometry was unchanged but transfer factor was 38% pre-
dicted. Arterial blood sampling breathing room air at rest showed
paO2 of 56 and paCO2 of 34 mmHg. After 30 min breathing 98% O2,
the values were 128 and 34 mmHg respectively, giving a calculated
shunt of approximately 27%.1 A microaggregate study showed no
intrapulmonary shunt. Repeat echocardiography showed normal
left and right ventricular appearances and function. There was mild
tricuspid regurgitation with an estimated right ventricular systolic
pressure of 30 mmHg by Doppler. Magnetic resonance imaging of
the heart was normal. Repeat high-resolution CT scan showed the
impression of very subtle diffuse nodular opacities. Open lung
biopsy showed scanty small foci of interstitial ﬁbrosis, but no
widespread pulmonary ﬁbrosis. There were focal areas of capillary
congestion within lobules, but no actual double layer of capillaries,
or extension of capillaries into the interstitium, interlobular septa
or bronchioles. Haemosiderin laden macrophages were prominent
in alveolar spaces. Occasional small veins showed evidence of
sclerosis, but there was no deﬁnite occlusion of veins and these
changes were felt to be insufﬁcient to make a diagnosis of
pulmonary veno-occlusive disease (PVOD). There were some
regions of increased cellularity in the alveolar walls, reminiscent of
pulmonary capillary haemangiomatosis (PCH), but again, insufﬁ-
cient to conﬁrm this diagnosis. Overall, therewas some suspicion of
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to be non-diagnostic. A vasculitic process was also considered
possible.
Warfarin and long-term oxygen therapy were commenced. On
the basis that a vasculitic process was possible, a trial of methyl-
prednisolone and pulsed cyclophosphamide was started. However,
further deterioration occurred and he died approximately 3 years
after initial presentation.
Postmortem examination of the heart and lungswas performed.
There was biventricular hypertrophy. Sections of the heart demon-
strated intraventricular septal hypertrophy with thickness of 20e
22 mm. The circumferential thickness of the left ventricle was
16 mm (normal 13e15 mm). Right ventricular thickness was 6 mm
(normal 3e5 mm). Histology of the lungs showed mild pulmonary
arterialmedial hypertrophyandcongestion in the lower lobes. There
were multiple focal capillary proliferations within alveolar and
bronchiolar walls throughout all areas examined (Fig. 1). There was
associated fresh haemorrhage but little evidence of old haemor-
rhage. Venous occlusive lesions were not identiﬁed. The capillary
proliferations were felt to be sufﬁcient to diagnose PCH.
PCH was ﬁrst described by Wagenvoort2 in 1978. It is a rare
disorder of alveolar capillary proliferation and presents with
features similar to idiopathic pulmonary hypertension or PVOD.3
There are fewer than 40 reported cases. The typical patient is aged
20e40 years and there is an equal sex incidence.4 Prognosis is poor
and median survival is 3 years,5 with a typical clinical course of
progressive, unrelenting symptoms of pulmonary hypertension.6
The hallmark of histology is proliferation of small capillaries
within the interstitium and alveolar walls.2 One report suggested
considerable overlap histologically between PVOD and PCH with
features of PCH present in cases of PVOD and vice versa.6Fig. 1. a) Low power of the lung with expansion by multiple interlacing capillary channels ﬁl
of the lung with expansion by multiple interlacing capillary channels ﬁlled with red blood
nostaining with CD31. Several capillary layers/channels are visible within the lung interstitCommon clinical features of PCH are dyspnoea and right heart
failure. Haemoptysis, pleural effusion and acropachy occur less
commonly.5 Clinically, PCH is difﬁcult to distinguish from PVOD.
Progressive dyspnoea and fatigue are common to both.8 Hae-
moptysis and haemorrhagic pleural effusions occur in 30% of PCH
but not with PVOD.9
Our case was unusual in the paucity of radiological abnormali-
ties. Only when the disease was very advanced did very subtle CT
abnormalities become evident. Characteristic CT ﬁndings in PCH
include diffuse bilateral thickening of the interlobular septae and
small centrilobular, poorly circumscribed nodular opacities. Septal
lines are present in both PCH and PVOD, but are more numerous in
PVOD than PCH. Conversely, the presence of visible, better cir-
cumscribed ground glass opacities is more suggestive of PCH than
PVOD.10
Hypoxia is not uncommon in PCH. In our patient, the cardio-
pulmonary exercise test and the high FiO2 study were physiologi-
cally in keeping with signiﬁcant right to left shunt, but no shunt
could be identiﬁed anatomically. A patent foramen ovale is unlikely
to have been responsible as pulmonary hypertension was mild. We
postulate that a small-vessel intrapulmonary shunt was respon-
sible, with shunting occurring through the capillary proliferation
present as part of the disease. In PCH elevated pulmonary arterial
pressures and normal/low pulmonary capillary wedge pressures
are seen.7 Pulmonary hypertension was unusually mild in our case,
and it is possible that shunting through capillary channels resulted
in relatively low pulmonary vascular resistance and pulmonary
arterial pressures.
The diagnosis in our patient was not made ante-mortem, and
empirical therapy proved futile. There are no randomised
controlled trials to provide evidence for the safety and efﬁcacy ofled with red blood cells. Haematoxylin and eosin 200 magniﬁcation. b) Higher power
cells. Haematoxylin and eosin 400 magniﬁcation. c) Lung section showing immu-
ium.
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cyclophosphamide has proved ineffective in several cases,11
although one case of PCH with atypical endotheliomatosis was
successfully treated with doxycycline.11 In contrast to idiopathic
pulmonary arterial hypertension, in which epoprostenol therapy is
effective, prostanoids show deleterious effects in PCH.5
In summary, we present a case of PCH showing no diagnostic
radiological features despite otherwise severe disease. Our case
illustrates the diagnostic and therapeutic difﬁculties associated
with PCH.
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